Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference
Journey Medical Corporation (DERM)
Last journey medical corporation earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.dermira.com
Company Research
Source: Business Wire
- Detailed primary results of lebrikizumab Phase 2b study to be presented at the Fall Clinical Dermatology Conference- Data reflect potential of lebrikizumab to offer best-in-disease combination of safety, efficacy, tolerability, convenience and ease of use- Conference call and webcast to be held on October 17 to discuss data and provide overview of Phase 3 clinical development program MENLO PARK, Calif.--(BUSINESS WIRE)--Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that detailed primary results of its Phase 2b study of lebrikizumab in patients with moderate-to-severe atopic dermatitis will be reported at the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV, October 17-20, 2019. In addition, the company will host a conference call and webcast on October 17, 2019, duri
Show less
Read more
Impact Snapshot
Event Time:
DERM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DERM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DERM alerts
High impacting Journey Medical Corporation news events
Weekly update
A roundup of the hottest topics
DERM
News
- Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA [Yahoo! Finance]Yahoo! Finance
- Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaGlobeNewswire
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 [Yahoo! Finance]Yahoo! Finance
DERM
Earnings
- 11/7/23 - Beat
DERM
Sec Filings
- 3/27/24 - Form 4
- 3/25/24 - Form 4
- 3/25/24 - Form 4
- DERM's page on the SEC website